Heart Age and Cardiovascular Risk
|
|
- Paul Parrish
- 5 years ago
- Views:
Transcription
1 Heart Age and Cardiovascular Risk Mark Cobain Unilever R+D Colworth Science Park Sharnbrook Bedfordshire Europrevent, Geneva April
2 Conflict of Interest Statement Employment by Unilever PLC A producer of consumer goods (foods, home and personal care products) Funded the development of the Heart Age Tool
3 Differing applications of CVD Risk Scores 1. To identify disease-free individuals at highest risk of incident CVD Requires risk scores should accurately rank order individuals in terms of risk 2. To help in making decisions about treatment options for prevention of CVD (Absolute risk thresholds) Requires risk scores to accurately identify which individuals meet a particular risk threshold 3. To communicate risk and promote understanding Requires output that facilitates alignment of perceived risk with actual risk 4. To motivate risk reduction behaviours Requires output that promotes adherence to medication, lifestyle changes
4 Differing applications of CVD Risk Scores 1. To identify disease-free individuals at highest risk of incident CVD Requires risk scores should accurately rank order individuals in terms of risk 2. To help in making decisions about treatment options for prevention of CVD (Absolute risk thresholds) Requires risk scores to accurately identify which individuals meet a particular risk threshold 3. To communicate risk and promote understanding Requires output that facilitates alignment of perceived risk with actual risk 4. To motivate risk reduction behaviours Requires output that promotes adherence to medication, lifestyle changes
5 % change in FRS from baseline REACH-OUT study 0 Usual care Intervention % P< % FRS= Framingham Risk Score Benner et al., Int J Clin Practice 2008
6 30 year-old female Problems with 10 year risk Overweight Smokes SBP 160mmHg TC 6.2mmol/L HDL-C 1.0mmol/L Potential for False Reassurance Women screened and given low risk category status believed they did not need to change their lifestyle Tjimstra and Bieleman, J Fam Practice year CVD risk 6.5% At 60 years of age the CVD risk would be 29.5% (not accounting for any further increases in risk factors )
7 What is Heart Age? The age at which an individuals estimated % CVD risk would be considered normal Normal risk factors defined by midpoint of normal range Systolic Blood Pressure 125mmHg No hypertensive medication Total cholesterol 180mg/dL HDL cholesterol 45mg/dL (men) Non smoking Non diabetic D Agostino et al., 2008 Circulation
8 Example 30 year-old female Overweight Smokes SBP 160mmHg TC 6.2mmol/L HDL-C 1.0mmol/L % CVD: 6.5% Heart-Age: >45
9
10 Heart Forecast Tool (New Zealand) Courtesy of Prof Rod Jackson
11 Heart Age Tool User Process Patient Input CVD Risk Factors Demographic Info Heart Age Calculation High heart age CVD Risk > normal risk for age Low heart age CVD Risk< normal risk for age Tailored Personal Recommendations Diet, physical activity, smoking etc Sign Up for D+L Plan newsletter with guidelines for diet and lifestyle change
12 Heart Age by Age Group and Gender All data to end of December 2010 Mean Heart Age (recalculated) - Age, by age group Average Age = 42 Average Heart Age = 48 54% Female 46% Male Age group All data to end Mean of December Heart Age-Age 2010 Mean Heart Age (recalculated) - Age, by gender and age group Average Agp Gap = 6yrs Age group / Gender Male Female Male Female Male Female Male Female Male Female Male Female Male Female Male Female Male Female Male Female Male Female Male Female Mean Heart Age-Age
13 Users who sign up for a plan are less healthy Heart Age Age (yrs) sign up no sign up 2 0 men women
14 (Self Reported) Risk factor profile of those who sign up for a plan Mean Total Cholesterol = 204mg/dL Mean Systolic Blood Pressure = 130mmHg Prevalence of Diabetes = 4.2% Prevalence of Smoking = 28.5%
15 How close is perceived risk to actual risk? Does presentation of risk stimulate health promotion and risk reduction?
16 Risk Perception Trial 413 UK participants recruited online Ages years (mean=45yrs) Participants were smokers or/and obese BMI>29 (mean=30.5) 204 randomly assigned to Heart Age message & 209 to % CVD risk Questionnaire Risk Perception Emotional Response Motivation to Change Lifestyle
17 Measured CVD risk (%) Perceived risk is closer to actual risk after exposure to Heart Age Perceived risk Low Moderate High 'CVD Risk' 'Heart Age' Type of risk presented to user N=413, BMI>30 or smoking Soureti et al., EJCPR (2010)
18 Control 'Heart Age' Intentions Heart Age +Intentions Health Plan Sigm Up Rate (%) Health Plan Sign Up Rates 80 * * P<.01 vs all Experimental Condition Ayres et al., submitted
19 % Awareness of cholesterol increases with age cholesterol known cholesterol not known
20 Validation of Risk Model that uses BMI to replace cholesterol and HDL (D Agostino et al., 2008) Full CVD risk model non lipid CVD risk model Risk category 0 to 5 6 to >20 Total Participants who do not experience an event 0 to 5% 677 (20.1) 179 (5.3) 1 (0) 0 (0) to10% 80 (2.4) 609 (18.1) 179 (5.3) 2 (0.1) to 20% 3 (0.1) 121 (3.6) 652 (19.3) 131 (3.9) 907 >20% 0 (0) 2 (<0.1) 123 (3.7) 615 (18.2) 740 Total Participants who do experience an event 0 to 5% 9 (1.5) 6(1.0) 0 (0) 0 (0) 15 6 to 10% 6 (1.0) 41 (6.9) 16 (2.7) 0 (0) to 20% 1 (0.2) 21 (3.5) 104 (17.5) 26 (4.4) 152 >20% 0(0) 1 (0.2) 39 (6.6) 325 (54.6) 365 Total Net reclassification index score of -8% - meaning overall 8% of men misclassified by non lipid model
21 Validation of Risk Model that uses BMI to replace cholesterol and HDL (D Agostino et al., 2008) Full CVD risk model non lipid CVD risk model Frequency (Row per cent) 0 to 5 6 to >20 Total Participants who do not experience an event 0 to 5% 2088 (50.1) 171 (4.1) 0 (0) 0 (0) to10% 105(2.5) 691 (16.6) 135(3.2) 0 (0) to 20% 1 (<0.1) 107 (2.6) 495 (11.9) 61 (1.5) 664 >20% 1 (<0.1) 0 (0) 73 (1.8) 238 (5.7) 312 Total Participants who do experience an event 0 to 5% 34 (9.6) 7 (2.0) 0 (0) 0 (0) 41 6 to 10% 9 (2.5) 47 (13.2) 13 (3.7) 0 (0) to 20% 0 (0) 18 (5.1) 97 (27.3) 11 (3.1) 126 >20% 0 (0) 0 (0) 18 (5.1) 102 (28.7) 120 Total Net reclassification index score of -6% - meaning overall 6% of women misclassified by non lipid model
22 Using Heart Age as a platform for behaviour change in the community Online Media Screening Events Health Care Professionals Retail Grocery Insurers Hospital Pharmacy
23 World Heart Federation unbranded tool
24 Canada: Activation with Heart and Stroke Foundation digital In store workplace press tv events
25 Private Sector Collaborations
26 30 year-old female False Reassurance Potential? Overweight Poor Diet Inactive/Sedentary Classic Risk Factors normal Family History of Diabetes % CVD: 1% Heart-Age: 30
27 How to bring in the proximal predictor Cardiovascular Disease variables? Clinical risk factors BP Chol/HDL Diabetes Inflammation metabolism Adiposity Metabolic Dysregulation lifestyle Diet Activity Stress Smoking
28 Conclusions Communicating personal CVD risk to patients and the public has the potential to enhance risk reduction behaviours (drugs, lifestyle) Presenting this in the form of a Heart Age enhances the perception of risk in line with actual risk In combination with lifestyle change messages can promote risk reduction behaviour More research is needed to effectively integrate diet and lifestyle measures to avoid false reassurance
29 Colleagues and Collaborators Unilever Colworth, UK Natasha Soureti Bob Hurling Peter Murray Cambridge University, UK Anna Fair Oscar Franco Boston University Ralph D Agostino Sr Ramachandran Vasan Joe Massaro Michael Pencina Auckland University Rod Jackson Susan Wells
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
More informationCardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationEuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
More informationKey causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population
More informationUnderstanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationBeyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital
Beyond Framingham Prediction of cardiovascular risk Niels van Pelt Cardiologist, Middlemore Hospital Niels Bohr (Danish Physicist)1885-1962 Prediction is very difficult, especially if it's about the future
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationDepok-Indonesia STEPS Survey 2003
The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationThe Physician, the Community and Health Care Reform
International Journal of Health Sciences Published by American Research Institute for Policy Development URL: http://www.healthe-link.com/aripd/ijhs/ijhsbofv3n1p1_7.pdf CDC grant award H75DP002301-01 Healthy
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationCVD risk calculation
CVD risk calculation Cardiovascular disease (CVD) is the most common cause of death in Alberta, accounting for nearly one third (31%) of the overall deaths (1). The majority (90%) of the CVD cases are
More informationSAMPLE 100 DAY JOURNEY GLOBAL BASELINE REPORT
100 DAY JOURNEY GLOBAL BASELINE REPORT LIFESTYLE HABITS The day-to-day choices Global Challenge members make around physical activity, nutrition, psychological wellbeing and sleep can impact their performance.
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationClasses of recommendations
Classes of recommendations Levels of evidence Quality of evidence used in GRADE Percentage of the decrease in deaths from coronary heart disease attributed to treatments and risk factor changes in different
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More informationSaffolalife Study 2013
Saffolalife Study 2013 Disclaimer: *Based on the number of responses received on the Saffolalife Heart Age Finder Test. Saffolalife Study is based on an analysis of information shared on the site www.saffolalife.com
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationEuroPRevent Risk assessment models: what is to come? Risk Assessment Models: Applications in Clinical Practice
EuroPRevent 2010 Risk assessment models: what is to come? Risk Assessment Models: Applications in Clinical Practice G. De Backer Ghent University Ghent, Belgium May 5-8 2010, Prague Czech Republic G. De
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationCommunity Health Needs Assessment. Implementation Strategy.. SAMPLE TEMPLATE
Community Health Needs Assessment & Implementation Strategy SAMPLE TABLE OF CONTENTS Executive Summary I. Service Area and Population II. Community Health Needs Assessment Partners.. III. IV. Community
More informationMississippi Stroke Systems of Care
Stroke Initiatives Mississippi State Department of Health Cassandra Dove, Chronic Disease Bureau 19 th Annual Stroke Belt Consortium March 1, 2014 Mississippi Stroke Systems of Care Heart Disease and Stroke
More informationHEALTH TARGETS IN PRIMARY CARE
HEALTH TARGETS IN PRIMARY CARE MORE HEART AND DIABETES CHECKS BETTER HELP FOR SMOKERS TO QUIT Better Help for Smokers to Quit 90% of enrolled patients who smoke and are seen by General Practice, will be
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More information2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of
More informationNotes Indicate to the group that this patient will be the focus of today s case discussion.
1 Indicate to the group that this patient will be the focus of today s case discussion. Read out the case authors and their disclosure information. Instructions Fill out prior to the meeting and disclose
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationFitFormula. Sam Liu (Apper) Simran Fitzgerald (Programmer) Jonathan Tomkun (Programmer) ECE1778 Final report
FitFormula ECE1778 Final report Sam Liu (Apper) Simran Fitzgerald (Programmer) Jonathan Tomkun (Programmer) Final Report Word Count: 1951 Apper Context Word Count: 311 Contents 1.0 Introduction... 3 2.0
More informationTask Force Finding and Rationale Statement
Cardiovascular Disease Prevention and Control: Reducing Out-of- Pocket Costs for Cardiovascular Disease Preventive Services for Patients with High Blood Pressure and High Cholesterol Task Force Finding
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationAn evaluation of body mass index, waist-hip ratio and waist circumference as a predictor of hypertension across urban population of Bangladesh.
An evaluation of body mass index, waist-hip ratio and waist circumference as a predictor of hypertension across urban population of Bangladesh. Md. Golam Hasnain 1 Monjura Akter 2 1. Research Investigator,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationTo reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.
E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs
More informationLifetime vs. 10-year risk to allocate treatments for the primary prevention of cardiovascular disease
Lifetime vs. 10-year risk to allocate treatments for the primary prevention of cardiovascular disease Eleni Rapsomaniki Farr Institute for Health Informatics Research, Epidemiology & Public Health University
More informationCommunity Impact Through Data-Driven Action Teams
Community Impact Through Data-Driven Action Teams Who is in the room? The Heart of New Ulm Project What if we could eliminate heart attacks in an entire community? New Ulm Primary Objective Improve the
More informationTrends In CVD, Related Risk Factors, Prevention and Control In China
Trends In CVD, Related Risk Factors, Prevention and Control In China Youfa Wang, MD, MS, PhD Associate Professor Center for Human Nutrition Department of International Health Department of Epidemiology
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationHealth Improvement Initiative
The City of Dalton Health Improvement Initiative Case Study: City of Dalton Chronic Disease Risk Reduction Program Improved Health and Lowered Costs EXPERIENCE TRUE HEALTH 5 Batterson Park Rd, Suite 1
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationMetabolic Syndrome and Workplace Outcome
Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationPrevention of Cardiovasular Diseases
Role and Significance of In-Vitro-Diagnostics in the Healthcare Systems of the Future Prevention of Cardiovasular Diseases Michael Walter Charité University Medicine, Berlin & Unfallkrankenhaus Berlin
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHypertension and cardiovascular risk factors: intervention by the family physician
Hypertension and cardiovascular risk factors: intervention by the family physician Hypertension is a common presentation and a known risk factor for cardiovascular disease. L H MABUZA MB ChB, BTh, MFamMed
More informationCARE PATHWAYS. Allyson Ashley
CARE PATHWAYS Allyson Ashley WHAT IS A CARE PATHWAY? An explicit statement of the goals and key elements of care based on evidence, best practice, and patient s expectations and their characteristics The
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More information24-uur ambulante bloeddrukmeting versus thuisbloedrukmeting
2017 Dementia 24-uur ambulante bloeddrukmeting versus thuisbloedrukmeting Wat gebruiken in de klinische praktijk? Jan A. Staessen, MD, PhD KU Leuven jan.staessen@kuleuven.be BPM Key messages to be made
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationClinical Investigations
Clinical Investigations Time-Trend Analysis on the Framingham Risk Score and Prevalence of Cardiovascular Risk Factors in Patients Undergoing Percutaneous Coronary Intervention Without Prior History of
More informationReport Operation Heart to Heart
Report Operation Heart to Heart Elkhorn Logan Valley Public Health Department (Burt, Cuming, Madison, and Stanton Counties) Gina Uhing, Health Director Ionia Research Newcastle, Nebraska Joseph Nitzke
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More informationCardiovascular disease - from management to prevention
Cardiovascular disease - from management to prevention Reflections originating from the Fourth Joint European Societies Task Force on Cardiovascular Disease Prevention in Clinical Practice 2007 WHAT IS
More informationBridging health promotion intervention policy with behavioral risk factor surveillance in Thailand
Bridging health promotion intervention policy with behavioral risk factor surveillance in Thailand The 7 th World Alliance for Risk Factor Surveillance (WARFS) Global Conference Toronto, Ontario, Canada,
More informationMetabolic Syndrome: A Preventable & Treatable Cluster of Conditions
Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions April D. McNeill MD Candidate 2016, Southern Illinois University, School of Medicine GE-NMF Primary Care Leadership Program, July 2013
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None Dietary changes and its influence on cardiovascular diseases in Asian and European countries Problems of Eastern European countries for cardiovascular disease prevention
More informationprogramme. The DE-PLAN follow up.
What are the long term results and determinants of outcomes in primary health care diabetes prevention programme. The DE-PLAN follow up. Aleksandra Gilis-Januszewska, Noël C Barengo, Jaana Lindström, Ewa
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationTHE EFFECT OF SECONDHAND SMOKE EXPOSURE ON HIGH MOLECULAR WEIGHT ADIPONECTIN LEVELS IN ADULT WOMEN: A PRELIMINARY REPORT
THE EFFECT OF SECONDHAND SMOKE EXPOSURE ON HIGH MOLECULAR WEIGHT ADIPONECTIN LEVELS IN ADULT WOMEN: A PRELIMINARY REPORT Siti Hajar MH 1, Harmy MY 1, Norhayati MN 1, Aida HGR 2, Hamid JJM 3 Department
More informationArticle by Anette Marina Rodrigues Nursing, Texila American University, India Abstract
Perception of Patients about Cardiovascular Disease (CVD) and Effect of Communication by Physician and the Assisting Registered Nurse to Enhance Assessment of Risk and Bridge a Gap of Accurate Perception
More informationThe Importance of Local Research in Developing Health Strategy The Case of Cardiovascular Disease Prevention in Sri Lanka
The Importance of Local Research in Developing Health Strategy The Case of Cardiovascular Disease Prevention in Sri Lanka Dr Ravi P. Rannan-Eliya, Dr Nilmini Wijemanne Institute for Health Policy KDU International
More informationSince 1980, obesity has more than doubled worldwide, and in 2008 over 1.5 billion adults aged 20 years were overweight.
Impact of metabolic comorbidity on the association between body mass index and health-related quality of life: a Scotland-wide cross-sectional study of 5,608 participants Dr. Zia Ul Haq Doctoral Research
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationType of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis.
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients Milne R J, Hoorn S V, Jackson R T Record
More informationReducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf
Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Disclosure None Polypill & CVD Prevention 1. Why do we need a polypill? 2. What components in the polypill?
More informationWomen and Heart Disease : Separating Fact from Fiction
Women and Heart Disease : Separating Fact from Fiction Maria T. Vivaldi M.D. Director of Education MGH Women s Heart Health Program Corrigan Minehan Heart Center Women and Heart Disease : Separating Fact
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationProf. Renata Cífková, MD, CSc.
Prof. Renata Cífková, MD, CSc. Head of the Department of Preventive Cardiology, Thomayer Teaching Hospital, Prague Focuses on arterial hypertension epidemiology, clinical trials, target organ damage prevention
More informationUnderstanding the metabolic syndrome
Understanding the metabolic syndrome Understanding the metabolic system Metabolic syndrome is the clustering together of a number of risk factors for heart disease, stroke and diabetes. Having one of these
More informationStudent Paper PRACTICE-BASED RESEARCH
The Role of Clinical Pharmacists in Modifying Cardiovascular Disease Risk Factors Autumn Bagwell, PharmD. 1 ; Jessica W. Skelley, PharmD 2 ; Lana Saad, PharmD 3 ; Thomas Woolley, PhD 4 ; and DeeAnn Dugan,
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationEffect of Combined Interventions of Diet and Physical Activity on the Perceived and Actual Risk of Coronary
World Journal of Medical Sciences 9 (4): 282-288, 2013 ISSN 1817-3055 IDOSI Publications, 2013 DOI: 10.5829/idosi.wjms.2013.9.4.12383 Effect of Combined Interventions of Diet and Physical Activity on the
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationCardiovascular risk factor appraisal art or science?
Cardiovascular risk factor appraisal art or science? Prof. Philip MacCarthy BSc MBChB (Hons) PhD FRCP Consultant Cardiologist Bupa Cromwell Hospital Clinics: Wednesday & Friday PM/Evening What are we trying
More informationReshaping the Enrollment Strategy: Creating a Health Management Program That Sustains Employee Engagement
Reshaping the Enrollment Strategy: Creating a Health Management Program That Sustains Employee Engagement What s my why? Making your tomorrow a healthier today Americas weight problem 69% of U.S. adults
More informationImprove the Adherence, Save the Life
Improve the Adherence, Save the Life Park, Chang Gyu Korea University Guro Hospital Cardiovascular Center Seoul, Korea Modifiable CVD Risk Factors Obesity BMI Hypertension Cholesterol LDL HDL Diabetes
More information